KR101481844B1 - Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분 - Google Patents

Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분 Download PDF

Info

Publication number
KR101481844B1
KR101481844B1 KR20087026232A KR20087026232A KR101481844B1 KR 101481844 B1 KR101481844 B1 KR 101481844B1 KR 20087026232 A KR20087026232 A KR 20087026232A KR 20087026232 A KR20087026232 A KR 20087026232A KR 101481844 B1 KR101481844 B1 KR 101481844B1
Authority
KR
South Korea
Prior art keywords
ser
gly
antibody
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20087026232A
Other languages
English (en)
Korean (ko)
Other versions
KR20080113262A (ko
Inventor
엠마 수잔 코헨
랄프 레이몬드 민터
파울라 로자먼드 해리슨
매튜 알렉산더 슬리먼
앤드류 도날드 나쉬
루이스 제리 파브리
Original Assignee
메디뮨 리미티드
제니스 오퍼레이션스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 제니스 오퍼레이션스 피티와이 리미티드 filed Critical 메디뮨 리미티드
Publication of KR20080113262A publication Critical patent/KR20080113262A/ko
Application granted granted Critical
Publication of KR101481844B1 publication Critical patent/KR101481844B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
KR20087026232A 2006-03-27 2007-03-27 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분 Active KR101481844B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
US60/786,569 2006-03-27
PCT/GB2007/001108 WO2007110631A1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029959A Division KR101451546B1 (ko) 2006-03-27 2007-03-27 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분

Publications (2)

Publication Number Publication Date
KR20080113262A KR20080113262A (ko) 2008-12-29
KR101481844B1 true KR101481844B1 (ko) 2015-01-13

Family

ID=38293698

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20087026232A Active KR101481844B1 (ko) 2006-03-27 2007-03-27 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
KR1020137029959A Active KR101451546B1 (ko) 2006-03-27 2007-03-27 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137029959A Active KR101451546B1 (ko) 2006-03-27 2007-03-27 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분

Country Status (15)

Country Link
US (8) US8263075B2 (https=)
EP (3) EP1999152B1 (https=)
JP (2) JP5335662B2 (https=)
KR (2) KR101481844B1 (https=)
CN (3) CN103641915B (https=)
BR (1) BRPI0709259B1 (https=)
CA (1) CA2647449C (https=)
DK (3) DK1999152T3 (https=)
ES (3) ES2395839T3 (https=)
MX (2) MX2008012291A (https=)
PL (3) PL2423229T3 (https=)
PT (3) PT1999152E (https=)
RU (2) RU2495050C2 (https=)
SI (3) SI1999152T1 (https=)
WO (1) WO2007110631A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2527590B2 (ja) 1988-02-17 1996-08-28 三洋電機株式会社 空冷式吸収冷凍機
MX2008012291A (es) * 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
EP2101780B1 (en) * 2006-11-21 2013-10-09 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EP2282757B1 (en) * 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
CA2747206C (en) 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
CN102271705A (zh) * 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
US20120116059A1 (en) * 2009-05-05 2012-05-10 Morphosys Ag Treatment For M Treatment For Multiple Sclerosis
US20120165220A1 (en) * 2009-09-03 2012-06-28 Colgan Sean P Uses of CD116 Expression Level
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
CA2856329A1 (en) * 2011-11-17 2013-05-23 Glia Sp Z.O.O. Compositions and methods for treating glioma
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2014068029A1 (en) 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
TR201905447T4 (tr) 2012-12-14 2019-05-21 Biontech Rna Pharmaceuticals Gmbh Yeni mhc bağımsız tümörle ilişkili antijenler.
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
CN106456761A (zh) 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2017270027B2 (en) 2016-05-24 2024-07-11 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
AU2019377515A1 (en) * 2018-11-09 2021-05-27 Kiniksa Pharmaceuticals, Gmbh Treatment for giant cell arteritis
CN116003597A (zh) * 2018-11-27 2023-04-25 舒泰神（北京）生物制药股份有限公司 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
US20220331425A1 (en) 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
WO2021141986A1 (en) * 2020-01-07 2021-07-15 St. Jude Children's Research Hospital, Inc. Chimeric gmcsf-il18 receptor
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
EP4263597A2 (en) * 2020-12-18 2023-10-25 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
CN116887856A (zh) * 2022-01-20 2023-10-13 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
EP0486572B1 (en) * 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5611394A (en) 1992-11-19 1994-06-08 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
MX2008012291A (es) * 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Infect. Dis., Vol. 189, No. 11, pp. 2101-2109 (2004.05.12.) *
J. Infect. Dis., Vol. 189, No. 11, pp. 2101-2109 (2004.05.12.)*

Also Published As

Publication number Publication date
SI2423229T1 (sl) 2013-09-30
US8263075B2 (en) 2012-09-11
EP2423230A1 (en) 2012-02-29
RU2012157042A (ru) 2014-07-10
WO2007110631A1 (en) 2007-10-04
JP5335662B2 (ja) 2013-11-06
US20190040145A1 (en) 2019-02-07
SI1999152T1 (sl) 2013-02-28
US20140079708A1 (en) 2014-03-20
US9085628B2 (en) 2015-07-21
EP2423230B1 (en) 2013-05-08
BRPI0709259B1 (pt) 2022-05-31
JP5665894B2 (ja) 2015-02-04
PT2423230E (pt) 2013-08-26
ES2395839T3 (es) 2013-02-15
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
DK2423229T3 (da) 2013-08-05
DK1999152T3 (da) 2013-01-14
SI2423230T1 (sl) 2013-09-30
EP1999152B1 (en) 2012-09-19
US20240124596A1 (en) 2024-04-18
CN101443360A (zh) 2009-05-27
US20090130093A1 (en) 2009-05-21
DK2423230T3 (da) 2013-08-05
EP1999152A1 (en) 2008-12-10
HK1166989A1 (en) 2012-11-16
PT1999152E (pt) 2013-01-07
PL2423230T3 (pl) 2013-10-31
US8506960B2 (en) 2013-08-13
JP2009533020A (ja) 2009-09-17
MX348827B (es) 2017-06-30
PL1999152T3 (pl) 2013-05-31
BRPI0709259A2 (pt) 2011-06-28
JP2013121350A (ja) 2013-06-20
KR101451546B1 (ko) 2014-10-16
ES2424468T3 (es) 2013-10-02
US20120141464A1 (en) 2012-06-07
KR20130140186A (ko) 2013-12-23
RU2639546C2 (ru) 2017-12-21
US20150376285A1 (en) 2015-12-31
CN101443360B (zh) 2013-11-27
AU2007231128A1 (en) 2007-10-04
RU2495050C2 (ru) 2013-10-10
EP2423229B1 (en) 2013-05-08
PT2423229E (pt) 2013-08-22
ES2424467T3 (es) 2013-10-02
HK1166988A1 (en) 2012-11-16
US20210147559A1 (en) 2021-05-20
KR20080113262A (ko) 2008-12-29
US20190309077A1 (en) 2019-10-10
CN103641916A (zh) 2014-03-19
CN103641915B (zh) 2017-04-12
CA2647449C (en) 2017-05-16
EP2423229A1 (en) 2012-02-29
CN103641915A (zh) 2014-03-19
CA2647449A1 (en) 2007-10-04
RU2008137763A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
KR101481844B1 (ko) Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
AU2013200962B2 (en) Binding member for GM-CSF receptor
AU2007231128B2 (en) Binding member for GM-CSF receptor
HK1195323A (en) Binding member for gm-csf receptor
HK1195324A (en) Binding member for gm-csf receptor
HK1166988B (en) Binding member for gm-csf receptor
HK1195324B (en) Binding member for gm-csf receptor
HK1166989B (en) Binding member for gm-csf receptor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081027

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120323

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130912

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20131112

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140326

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20141023

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150106

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20171219

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20241216

Start annual number: 11

End annual number: 11